Literature DB >> 20238334

Antibiotics for community-acquired pneumonia in children.

Sushil K Kabra1, Rakesh Lodha, Ravindra M Pandey.   

Abstract

BACKGROUND: Pneumonia caused by bacterial pathogens is the leading cause of mortality in children in low-income countries. Early administration of antibiotics improves outcomes.
OBJECTIVES: To identify effective antibiotics for community acquired pneumonia (CAP) in children by comparing various antibiotics. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2009, issue 2) which contains the Cochrane Acute Respiratory Infections Group's Specialised Register; MEDLINE (1966 to September 2009); and EMBASE (1990 to September 2009). SELECTION CRITERIA: Randomised controlled trials (RCTs) in children of either sex, comparing at least two antibiotics for CAP within hospital or ambulatory (outpatient) settings. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data from full articles of selected studies. MAIN
RESULTS: There were 27 studies, which enroled 11,928 children, comparing multiple antibiotics. None compared antibiotic with placebo.For ambulatory treatment of non-severe CAP, amoxycillin compared with co-trimoxazole had similar failure rates (OR 0.92; 95% CI 0.58 to 1.47) and cure rates (OR 1.12; 95% CI 0.61 to 2.03). (Three studies involved 3952 children).In children hospitalised with severe CAP, oral amoxycillin compared with injectable penicillin or ampicillin had similar failure rates (OR 0.95; 95% CI 0.78 to 1.15). (Three studies involved 3942 children). Relapse rates were similar in the two groups (OR 1.28; 95% CI 0.34 to 4.82).In very severe CAP, death rates were higher in children receiving chloramphenicol compared to those receiving penicillin/ampicillin plus gentamycin (OR 1.25; 95% CI 0.76 to 2.07). (One study involved 1116 children). AUTHORS'
CONCLUSIONS: There were many studies with different methodologies investigating multiple antibiotics. For treatment of ambulatory patients with CAP, amoxycillin is an alternative to co-trimoxazole. With limited data on other antibiotics, co-amoxyclavulanic acid and cefpodoxime may be alternative second-line drugs. For severe pneumonia without hypoxia, oral amoxycillin may be an alternative to injectable penicillin in hospitalised children; however, for ambulatory treatment of such patients with oral antibiotics, more studies in community settings are required. For children hospitalised with severe and very severe CAP, penicillin/ampicillin plus gentamycin is superior to chloramphenicol. The other alternative drugs for such patients are ceftrioxone, levofloxacin, co-amoxyclavulanic acid and cefuroxime. Until more studies are available, these can be used as a second-line therapy.There is a need for more studies with larger patient populations and similar methodologies to compare newer antibiotics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20238334     DOI: 10.1002/14651858.CD004874.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  18 in total

1.  Differences in distribution and drug sensitivity of pathogens in lower respiratory tract infections between general wards and RICU.

Authors:  Ruoxi He; Bailing Luo; Chengping Hu; Ying Li; Ruichao Niu
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  Severe necrotizing pneumonia in a child with pandemic (H1N1) influenza.

Authors:  Jo Yazer; Michael Giacomantonio; Noni Macdonald; Steven Lopushinsky
Journal:  CMAJ       Date:  2010-12-06       Impact factor: 8.262

Review 3.  Concordance of effects of medical interventions on hospital admission and readmission rates with effects on mortality.

Authors:  Lars G Hemkens; Despina G Contopoulos-Ioannidis; John P A Ioannidis
Journal:  CMAJ       Date:  2013-10-21       Impact factor: 8.262

4.  Are parents of children hospitalized with severe community-acquired pneumonia more satisfied with care when physicians allow them to share decisions on the antibiotic route?

Authors:  Paola Rosati; Viviana Di Salvo; Stefania Crudo; Roberto D'Amico; Cecilia Carlino; Maria Rosaria Marchili; Michaela Gonfiantini; Vincenzo Di Ciommo
Journal:  Health Expect       Date:  2014-04-28       Impact factor: 3.377

5.  Better drug therapy for the children of Africa: current impediments to success and potential strategies for improvement.

Authors:  Stuart M Macleod; Janet K Finch; William M Macharia; Gabriel M Anabwani
Journal:  Paediatr Drugs       Date:  2013-08       Impact factor: 3.022

6.  Retrospective analysis of the efficacies of two different regimens of aqueous penicillin G administered to children with pneumonia.

Authors:  Alyson Brandão; Raquel Simbalista; Igor C Borges; Dafne C Andrade; Marcelo Araújo; Cristiana M Nascimento-Carvalho
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

Review 7.  Antibiotics for community-acquired pneumonia in children.

Authors:  Rakesh Lodha; Sushil K Kabra; Ravindra M Pandey
Journal:  Cochrane Database Syst Rev       Date:  2013-06-04

Review 8.  Treatment of severe community-acquired pneumonia with oral amoxicillin in under-five children in developing country: a systematic review.

Authors:  Rashmi Ranjan Das; Meenu Singh
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

Review 9.  Experience developing national evidence-based clinical guidelines for childhood pneumonia in a low-income setting--making the GRADE?

Authors:  Ambrose Agweyu; Newton Opiyo; Mike English
Journal:  BMC Pediatr       Date:  2012-01-01       Impact factor: 2.125

10.  Community-acquired lobar pneumonia in children in the era of universal 7-valent pneumococcal vaccination: a review of clinical presentations and antimicrobial treatment from a Canadian pediatric hospital.

Authors:  Anne Rowan-Legg; Nicholas Barrowman; Nazih Shenouda; Khaldoun Koujok; Nicole Le Saux
Journal:  BMC Pediatr       Date:  2012-08-28       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.